FDA approves atezolizumab with chemotherapy after surgery for stage III dMMR colon cancer
- On 8 October 2026 the FDA approved Tecentriq (atezolizumab) with chemotherapy as adjuvant treatment for stage III colon cancer.
- The atezolizumab approval covers mismatch repair deficient (dMMR) tumours in adults and children aged 2 and older.
- In the ATOMIC trial of 712 patients, atezolizumab cut the risk of recurrence or death by about 50%.
- A subcutaneous version of atezolizumab (Tecentriq Hybreza) was approved for the same use from age 12.
The US Food and Drug Administration approved Genentech's Tecentriq (atezolizumab) on 8 October 2026, combined with a fluoropyrimidine and oxaliplatin, as adjuvant treatment after surgery for adults and children aged 2 and older with stage III mismatch repair deficient (dMMR) colon cancer. A subcutaneous form (Tecentriq Hybreza) was approved for the same use in patients aged 12 and older weighing at least 40 kg.
The trial
Approval rests on the randomized ATOMIC trial of 711 adults and one child after complete removal of the tumour. Patients received either atezolizumab plus mFOLFOX6 for 12 cycles followed by 6 months of atezolizumab alone, or mFOLFOX6 alone.
Also read: FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer
Results
Atezolizumab halved the risk of recurrence or death (hazard ratio 0.50). In the published trial results, 3-year disease-free survival was 86.3% with atezolizumab versus 76.2% with chemotherapy alone. Overall survival, however, has not differed significantly between the groups so far.
Warnings
The label includes warnings for immune-mediated reactions, infusion reactions and harm to an unborn baby.
Sources: US Food and Drug Administration (FDA), AJMC
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What did the FDA approve for atezolizumab?
On 8 October 2026 the FDA approved atezolizumab (Tecentriq) with a fluoropyrimidine and oxaliplatin as adjuvant treatment after surgery for stage III dMMR colon cancer.
Who can receive atezolizumab for colon cancer?
Intravenous atezolizumab is approved for adults and children aged 2 and older; the subcutaneous form is for patients aged 12 and older weighing at least 40 kg.
How much did atezolizumab lower colon cancer recurrence?
In ATOMIC, atezolizumab plus chemotherapy cut the risk of recurrence or death by about 50% compared with chemotherapy alone.
Did atezolizumab improve overall survival?
Overall survival has not differed significantly between the ATOMIC trial groups so far, although recurrence was lower with atezolizumab.
What does dMMR colon cancer mean?
dMMR colon cancer is a tumour with a defect in the system that repairs DNA copying errors, a type that usually responds to immunotherapy such as atezolizumab.



